LAUSR

1 Molina-Torres CA, Barba-Marines A, Valles-Guerra O et al. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Ann Clin Microbiol Antimicrob 2014; 13: 13. 2 Taramona-Espinoza C, Preston Church LW, Steed LL. In vitro tedizolid minimum inhibitory concentration (MIC) against clinical isolates of Mycobacterium abscessus. In: Abstracts of IDWeek 2015, San Diego, CA, USA. Abstract P-581. 3 Colca JR, McDonald WG, Waldon DJ et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 2003; 278: 21972–9. 4 Shaw KJ, Poppe S, Schaadt R et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008; 52: 4442–7. 5 Flanagan S, McKee EE, Das D et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother 2015; 59: 178–85. 6 Shorr AF, Lodise TP, Corey GR et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2015; 59: 864–71. 7 Zhanel GG, Love R, Adam H et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs 2015; 75: 253–70. 8 Sasaki T, Takane H, Ogawa K et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother 2011; 55: 1867–73. 9 Brier ME, Stalker DJ, Aronoff GR et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47: 2775–80. 10 Flanagan S, Minassian SL, Morris D et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother 2014; 58: 6471–6. J Antimicrob Chemother 2017 doi:10.1093/jac/dkw465 Advance Access publication 17 November 2016